Nemonoxacin - TaiGen Biotechnology
Alternative Names: Nemonoxacin malate sodium chloride; Nenofloxacin; Taigexyn; TG-873870Latest Information Update: 27 Feb 2023
At a glance
- Originator Procter & Gamble
- Developer R-Pharm; TaiGen Biotechnology
- Class Antibacterials; Piperidines; Quinolones; Small molecules
- Mechanism of Action DNA topoisomerase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Marketed Community-acquired pneumonia
- Phase II Diabetic foot ulcer
- Phase Unknown Skin and soft tissue infections